A Phase 1 Study of IPI-145 in Patients With Advanced Hematologic Malignancies
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Safety and Tolerability
To determine the incidence of adverse events and abnormal laboratory test results, including dose-limiting toxicities.
At least 28 days (1 Cycle)
Patrick Kelly, MD
Infinity Pharmaceuticals, Inc.
United States: Food and Drug Administration
|New Britain, Connecticut 06052|
|Miami, Florida 33176|
|Albany, New York 12208|
|Cleveland, Ohio 44195|
|Nashville, Tennessee 37203-1632|
|Austin, Texas 78705|